Artelo Biosciences Inc (ARTL)
NASDAQ:ARTL
Want to see ARTL full AI Analyst Report?
Top Page
Artelo Biosciences
(NASDAQ:ARTL)
Select Model
Select Model
Rating:41Neutral
Price Target:
$4.50
▲(262.90% Upside)
Action:ReiteratedDate:04/18/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses and cash burn, and negative equity), reinforced by negative corporate developments (going-concern language, compliance pressure, and dilutive/high-cost financing). Technicals and valuation provide limited support, with the stock trading below key moving averages and a loss-driven negative P/E with no dividend.
Positive Factors
Multiyear equity facility
A committed equity purchase agreement through 2029 provides durable financing optionality: management can draw capital over multiple years to fund clinical programs without a single lump-sum raise, reducing the immediate liquidity cliff risk and supporting continued development of the pipeline if draws are executed responsibly.
Negative Factors
Negative stockholders' equity
Negative equity and an auditor’s going‑concern qualification materially weaken financial resilience. This condition constrains strategic choices, heightens regulatory and listing risk, and typically forces dilutive financing or asset sales to restore capital adequacy, undermining long-term shareholder value absent clinical successes.
Read all positive and negative factors
Positive Factors
Negative Factors
Multiyear equity facility
A committed equity purchase agreement through 2029 provides durable financing optionality: management can draw capital over multiple years to fund clinical programs without a single lump-sum raise, reducing the immediate liquidity cliff risk and supporting continued development of the pipeline if draws are executed responsibly.
Read all positive factors
Artelo Biosciences (ARTL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.74M
Dividend YieldN/A
Average Volume (3M)89.20K
Price to Earnings (P/E)―
Beta (1Y)-0.33
Revenue GrowthN/A
EPS Growth-22.52%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.66
Shares Outstanding708,257
10 Day Avg. Volume70,584
30 Day Avg. Volume89,202
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap2.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.84
Revenue Forecast (FY)N/A
Artelo Biosciences Business Overview & Revenue Model
Company Description
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled rece...
How the Company Makes Money
As a clinical-stage biotechnology company, Artelo Biosciences does not have a stable, product-based commercial revenue stream from marketed drugs (null for product sales revenue). The company primarily funds operations through financing activities...
Artelo Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Aug 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.54M | -10.11M | -9.93M | -10.08M | -7.44M |
| Net Income | -12.88M | -9.83M | -9.29M | -10.08M | -7.44M |
Balance Sheet | |||||
| Total Assets | 2.80M | 4.70M | 13.04M | 20.42M | 12.63M |
| Cash, Cash Equivalents and Short-Term Investments | 600.00K | 2.34M | 10.43M | 17.53M | 10.06M |
| Total Debt | 693.00K | 104.00K | 23.00K | 63.00K | 95.00K |
| Total Liabilities | 4.07M | 1.84M | 1.29M | 1.02M | 593.00K |
| Stockholders Equity | -1.27M | 2.86M | 11.75M | 19.40M | 12.04M |
Cash Flow | |||||
| Free Cash Flow | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M |
| Operating Cash Flow | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M |
| Investing Cash Flow | -62.00K | 7.77M | 3.51M | 2.96M | -3.44M |
| Financing Cash Flow | 6.87M | 112.00K | 567.00K | 0.00 | 14.11M |
Artelo Biosciences Technical Analysis
Negative
1.24
Price Trends
5.05
Negative
5.00
Negative
13.95
Negative
Market Momentum
-0.06
Positive
42.66
Neutral
12.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTL, the sentiment is Negative. The current price of 1.24 is below the 20-day moving average (MA) of 6.50, below the 50-day MA of 5.05, and below the 200-day MA of 13.95, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 42.66 is Neutral, neither overbought nor oversold. The STOCH value of 12.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARTL.
Artelo Biosciences Risk Analysis
Artelo Biosciences disclosed 56 risk factors in its most recent earnings report. Artelo Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Artelo Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $11.71M | -0.10 | -209.36% | ― | ― | 83.25% | |
46 Neutral | $6.08M | -0.13 | -317.98% | ― | ― | 34.57% | |
43 Neutral | $1.55M | -0.19 | -63.03% | ― | -100.00% | 86.75% | |
42 Neutral | $3.83M | -0.10 | -262.78% | ― | ― | 79.45% | |
41 Neutral | $4.74M | -0.22 | 1937.42% | ― | ― | -22.52% |
* Healthcare Sector Average
ARTL
Artelo Biosciences
4.44
-13.92
-75.82%
BDRX
Biodexa Pharmaceuticals
3.48
-65.52
-94.96%
TOVX
Theriva Biologics
0.26
-1.05
-80.38%
INDP
Indaptus Therapeutics
3.45
-9.57
-73.50%
ENVB
Enveric Biosciences
1.82
-12.46
-87.25%
Artelo Biosciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Artelo Biosciences Secures Bridge Financing Through Note Issuance
Negative
Mar 18, 2026
On March 12, 2026, Artelo Biosciences, Inc. entered into separate securities purchase agreements with Vanquish Funding Group Inc. and Boot Capital LLC, issuing 12% bridge notes with aggregate principal amounts of $237,300 and $113,000, respectivel...
Financial DisclosuresRegulatory Filings and ComplianceStock Split
Artelo Biosciences Enacts Reverse Stock Split Amid Strain
Negative
Mar 17, 2026
Artelo Biosciences executed a one-for-three reverse stock split of its common shares effective March 10, 2026, cutting its outstanding stock from 2,124,772 to about 708,323 shares and proportionally reducing authorized common and preferred share c...
Private Placements and Financing
Artelo Biosciences Secures Flexible Multiyear Equity Financing
Positive
Feb 5, 2026
On January 30, 2026, Artelo Biosciences, Inc. entered into an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5, giving the company the right, but not the obligation, to sell up to $25 million of its common stock...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder Meetings
Artelo Biosciences Granted Nasdaq Extension to Regain Compliance
Negative
Feb 5, 2026
On February 2, 2026, Artelo Biosciences said it received a decision from a Nasdaq Hearing Panel granting the company an exception to cure its listing deficiencies, provided it demonstrates by March 30, 2026 that it complies with the Nasdaq require...
Executive/Board ChangesShareholder Meetings
Artelo Biosciences Shareholders Back Board, Pay and Auditor
Positive
Jan 30, 2026
On January 30, 2026, Artelo Biosciences reconvened its previously adjourned Annual Meeting of Stockholders, achieving a quorum with approximately 50.4% of outstanding common shares represented. Shareholders re-elected Douglas Blayney, M.D., and Co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.